Zacks Investment Research downgraded shares of HERON THERAPEUT (HRTX) from N/A to NEUTRAL on February 24, 2014, with a target price of $14.30.
Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on HERON THERAPEUT (HRTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment